US FDA approves Sanofi's wearable injector form of blood cancer drug

The FDA has approved Sarclisa Escena, a wearable subcutaneous form of Sanofi's blood cancer drug, delivering the drug via on-body injector instead of intravenous infusion. The approval reduces patient treatment burden and clinic capacity strain while giving Sanofi a regulatory win under new leadership.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.